Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Squamous Cell Carcinoma of the Head and Neck (SCCHN): early-phase trial registry

A small indexed set (2 trials) with no open enrollment listed right now.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count

Squamous Cell Carcinoma of the Head and Neck (SCCHN): 2 US clinical trials tracked, none currently recruiting.

Squamous Cell Carcinoma of the Head and Neck (SCCHN) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Glenn J. Hanna, running 1 of these trials.

Enrollment posture brief

Registry condition squamous-cell-carcinoma-of-the-head-and-neck-scchn

OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Squamous Cell Carcinoma (th…0%
Open-enrollment share among volume-matched conditions near Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Squamous Cell Carcinoma of the Head and Neck (SCCHN) has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Squamous Cell Carcinoma of the Head and Neck (SCCHN) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Squamous Cell Carcinoma of the Head and Neck (SCCHN) is recruiting below its size-band peers.

    0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 21

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1

Top Sponsors

Glenn J. Hanna 1 trials
Pfizer 1 trials

Named interventions

Most-linked intervention names on Squamous Cell Carcinoma of the Head and Neck (SCCHN) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

sasanlimab Drug
1 trials
PF-08046037 Drug
1 trials
Duvelisib Drug
1 trials
Docetaxel Drug
1 trials

US sites by state

Facility locations filed on Squamous Cell Carcinoma of the Head and Neck (SCCHN) trials. A trial with sites in several states counts in each.

Tennessee 1 trials
Michigan 1 trials
Massachusetts 1 trials
Indiana 1 trials
Connecticut 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Squamous Cell Carcinoma of the Head and Neck (SCCHN) page

2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Squamous Cell Carcinoma of the Head and Neck (SCCHN) trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Glenn J. Hanna sponsors the most Squamous Cell Carcinoma of the Head and Neck (SCCHN) trials on record, review their full trial history before evaluating a specific study. See Glenn J. Hanna's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Squamous Cell Carcinoma of the Head and Neck (SCCHN) condition card totals 2 registered trials; most-linked intervention sasanlimab; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.